Rheumatology.net

Rheumatology Xagena

A study has evaluated the efficacy and safety of Adalimumab ( Humira ) in patients with juvenile idiopathic arthritis ( JIA ). Baseline demographic and clinical characteristics and disease activity ...


A study has investigated whether use of Adalimumab ( Humira ) decreases the frequency of attacks of anterior uveitis in patients with ankylosing spondylitis. Consecutive patients with ankylosing sp ...


High body mass index ( BMI ) is associated with increased risk of osteoarthritis ( OA ) and reduced risk of fragility fracture. However, the relationship between fragility fracture and osteoarthritis ...


Positive results from a phase 3 trial of investigational drug Sarilumab in rheumatoid arthritis ( RA ) patients who were inadequate responders to Methotrexate ( MTX ) therapy were presented at the Eur ...


The European Commission ( EC ) has granted a licence extension for Enbrel ( Etanercept ) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis ( nr-axSpA ). Non-ra ...


Results of the phase III POSTURE study evaluating Apremilast ( Otezla ), the oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), in patients with active ankylosing spondylitis. The Apremilast a ...


A new study presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) has shown a significantly increased risk of myocardial infarction in patients with Sjögren's syndrome ( S ...


Data presented at the European League Against Rheumatism Annual Congress ( EULAR 2014 ) have demonstrated the possibility of using biomarkers ( developed from whole blood gene expression profiles ) in ...


Conclusive data about cardiovascular toxicity of nonsteroidal anti-inflammatory drugs ( NSAIDs ) are sparse. It has been hypothesized that regular NSAID use is associated with increased risk for cardi ...


Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus Methotrexate or Methotrexate alone are unclear. ...


Two-year results from the ORAL Start study were published in The New England Journal of Medicine ( NEJM ). ORAL Start is a 24-month phase 3 study in patients with moderately to severely active rheumat ...


Decernotinib ( VX-509 ) is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis ( RA ). This was a 24-week, randomized, placebo-controlled, double-blind, phase 2 ...


Tofacitinib ( Xeljanz ) is an oral Janus kinase ( JAK ) inhibitor for the treatment of rheumatoid arthritis ( RA ). Phase 2, phase 3, and open-label long-term extension ( LTE ) studies have descri ...


Mavrilimumab and Sifalimumab have met their primary endpoints in respective phase II studies, demonstrating further pipeline progress in core therapeutic areas. Mavrilimumab, an investigational mon ...


The FDA ( Food and Drug Administration ) has approved Otezla ( Apremilast ), a oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of adult patients with active psoriatic arth ...


The aim of a study was to describe the long-term safety and efficacy profile of Tofacitinib ( Xeljanz ) in patients with moderate to severe active rheumatoid arthritis. Data were pooled from 2 open ...


The aim of a study was to assess long-term tolerability, safety, and efficacy of subcutaneous ( SC ) Abatacept ( Orencia ) in Methotrexate-refractory patients with rheumatoid arthritis. The phase I ...


Osteoarthritis is a leading cause of disability, characterized by the destruction of cartilage tissue in joints, but there is a lack of effective therapies because the underlying molecular causes have ...


Plasmacytoid dendritic cells have been implicated in the pathogenesis of systemic sclerosis through mechanisms beyond the previously suggested production of type I interferon.Researchers have isolated ...


Rheumatoid arthritis is a heterogeneous chronic disease, and no therapeutic agent has been identified which is universally and persistently effective in all patients. Researchers have investigated t ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati